Literature DB >> 34673998

Hyperosmolar dextrose injection for Osgood-Schlatter disease: a double-blind, randomized controlled trial.

Zhe Wu1, Xiaoxian Tu2, Zhiyuan Tu3.   

Abstract

OBJECTIVE: Osgood-Schlatter disease (OSD) is one of the common causes of long-term knee pain, leading to functional limitations, long-term deformity of the tubercle interfering with kneeling, and impaired peer-important sport participation. Nonetheless, patient management continues to rely on the usual conservative methods. This study examined the use of hyperosmolar dextrose injection in patients with OSD.
METHODS: We conducted a randomized, double-blind clinical trial involving 70 patients with OSD. One group received a hyperosmolar dextrose injection (12.5%), while the other received a saline injection. The injections were conducted under ultrasound guidance. The Victorian Institute of Sport Assessment (VISA) score was used to assess each patient's pain and sport level.
RESULTS: The dextrose group outperformed the saline group in improvement in the VISA-Patella (VISA-P) score from baseline to 3 months (27.1 ± 6.5 vs. 1.4 ± 2.6; mean difference 25.4 (22.4 to 28.3); p < .0001), 6 months (31.7 ± 7.9 vs. 25.2 ± 7.8; mean difference 6.2 (3.2 to 9.4); p < .0001), and 12 months (34 ± 9.0 vs. 28.2 ± 7.5; mean difference 5.5 (1.9 to 9.1); p = .0026). The changes in both groups were clinically important, suggesting that both therapies were active treatments. The dextrose group improved too rapidly for spontaneous improvement to explain much of this change.
CONCLUSION: After three injections, at the 6-month and 12-month follow-up visits, the VISA-P scores of the two groups were significantly improved; the dextrose group score was better than the saline group score, and there were significant differences between the two groups.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Hyperosmolar dextrose injection; Osgood–Schlatter disease; Prolotherapy; The VISA-P scale

Mesh:

Substances:

Year:  2021        PMID: 34673998     DOI: 10.1007/s00402-021-04223-1

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   2.928


  21 in total

1.  Prevalence and associated factors of Osgood-Schlatter syndrome in a population-based sample of Brazilian adolescents.

Authors:  Gildásio Lucas de Lucena; Cristiano dos Santos Gomes; Ricardo Oliveira Guerra
Journal:  Am J Sports Med       Date:  2010-11-12       Impact factor: 6.202

Review 2.  Treatment of Osgood-Schlatter disease: review of the literature.

Authors:  E Circi; Y Atalay; T Beyzadeoglu
Journal:  Musculoskelet Surg       Date:  2017-06-07

3.  Hyperosmolar dextrose injection for recalcitrant Osgood-Schlatter disease.

Authors:  Gastón Andrés Topol; Leandro Ariel Podesta; Kenneth Dean Reeves; Marcelo Francisco Raya; Bradley Dean Fullerton; Hung-wen Yeh
Journal:  Pediatrics       Date:  2011-10-03       Impact factor: 7.124

4.  Patellofemoral pain syndrome and its association with hip, ankle, and foot function in 16- to 18-year-old high school students: a single-blind case-control study.

Authors:  Carsten Mølgaard; Michael Skovdal Rathleff; Ole Simonsen
Journal:  J Am Podiatr Med Assoc       Date:  2011 May-Jun

5.  Responsiveness of the VISA-P scale for patellar tendinopathy in athletes.

Authors:  Sergio Hernandez-Sanchez; Ma Dolores Hidalgo; Antonia Gomez
Journal:  Br J Sports Med       Date:  2012-09-25       Impact factor: 13.800

6.  No superiority of dextrose injections over placebo injections for Osgood-Schlatter disease: a prospective randomized double-blind study.

Authors:  Junsuke Nakase; Takeshi Oshima; Yasushi Takata; Kengo Shimozaki; Kazuki Asai; Hiroyuki Tsuchiya
Journal:  Arch Orthop Trauma Surg       Date:  2019-11-11       Impact factor: 3.067

7.  High prevalence of daily and multi-site pain--a cross-sectional population-based study among 3000 Danish adolescents.

Authors:  Michael S Rathleff; Ewa M Roos; Jens L Olesen; Sten Rasmussen
Journal:  BMC Pediatr       Date:  2013-11-19       Impact factor: 2.125

8.  Risk assessment of the onset of Osgood-Schlatter disease using kinetic analysis of various motions in sports.

Authors:  Gento Itoh; Hideyuki Ishii; Haruyasu Kato; Yasuharu Nagano; Hiroteru Hayashi; Hiroki Funasaki
Journal:  PLoS One       Date:  2018-01-08       Impact factor: 3.240

9.  Long-term Prognosis and Impact of Osgood-Schlatter Disease 4 Years After Diagnosis: A Retrospective Study.

Authors:  Clara Guldhammer; Michael Skovdal Rathleff; Hans Peter Jensen; Sinead Holden
Journal:  Orthop J Sports Med       Date:  2019-10-31

10.  Pathogenic Factors Associated With Osgood-Schlatter Disease in Adolescent Male Soccer Players: A Prospective Cohort Study.

Authors:  Hiroyuki Watanabe; Meguru Fujii; Masumi Yoshimoto; Hiroshi Abe; Naruaki Toda; Reiji Higashiyama; Naonobu Takahira
Journal:  Orthop J Sports Med       Date:  2018-08-28
View more
  1 in total

Review 1.  Osgood-Schlatter Disease: Appearance, Diagnosis and Treatment: A Narrative Review.

Authors:  Francisco Corbi; Sergi Matas; Jesús Álvarez-Herms; Sebastian Sitko; Ernest Baiget; Joaquim Reverter-Masia; Isaac López-Laval
Journal:  Healthcare (Basel)       Date:  2022-05-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.